AbbVie and C2N’s humanised anti-tau antibody obtains FDA orphan drug status for PSP

AbbVie and C2N Diagnostics have received orphan drug designation from the US Food and Drug Administration (FDA) for their investigational recombinant humanised anti-tau antibody, C2N-8E12 (ABBV-8E12), to treat progressive supranuclear palsy (PSP).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news